June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Exosomes for the treatment of retinal diseases
Author Affiliations & Notes
  • Sun Young Lee
    Ophthalmology, USC Roski Eye Institute, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Sun Young Lee None
  • Footnotes
    Support  NEI K12EY028873, NEI R56EY034193
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2449. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sun Young Lee; Exosomes for the treatment of retinal diseases. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2449.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : Small-sized EV (<200 nm), including exosomes (30-150 nm), are major dictators for cell-to-cell communication by transferring functional biomolecules to the recipient cells. Our recent studies identified important advantages of intraocular EV therapy, such as 1) excellent retinal tissue penetration of exosomes after intravitreal injection and 2) no immediate reactive gliosis after IVT injection of the retinal multicell line-derived exosome, which supports intraocular EV therapy potentially with little or no toxicity and/or immunogenicity. Based on these favorable characteristics, exosomes hold great potential as a treatment for retinal diseases, including 1) an intraocular drug delivery vehicle and 2) cell-free regenerative therapeutics. For the first strategy to utilize exosomes as a drug delivery vehicle, we have developed ASL-exosomes composed of Anchor, Spacer, and Arg-Gly-Asp acid (RGD) Ligand modification. RGD is one of the major integrin-binding ligands. Integrins are essential in VEGF signaling in CNV. Intravitreally delivered RGD-modified exosomes actively targeted areas of CNV in the laser-induced mouse CNV model. To develop the cell-free regenerative therapeutics, we tested exosomes derived from hESC derived RPE to treat retinal degeneration. RCS rats treated with intravitreal injection of hESC-RPE-Exo were able to rescue photoreceptors and their function.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×